1. Overview of the K-AI Drug Discovery Federated Learning Program
The K-AI Drug Discovery Federated Learning Model Program, launched by Korea's Ministry of Health and Welfare in 2026, is a major national R&D initiative that introduces artificial intelligence and federated learning into drug discovery at full scale.
The program's strategic focus is not merely AI model development, but building a federated learning infrastructure that enables multi-institutional learning without moving sensitive medical data.
2. How Federated Learning Transforms Drug Discovery
Balancing Data Security and Learning Efficiency
Traditional AI drug discovery required centralizing training data—nearly impossible under PIPA, GDPR, and HIPAA. Federated learning overcomes this barrier.
Acceleration and Success Rate Improvement
Global benchmarks show federated learning–based drug discovery delivers:
Europe's MELLODDY consortium (10 global pharma companies) is a leading reference; K-AI aims to develop a Korean-adapted version.
3. Participation Strategy for SME Bio Companies
Consortium Formation and Role Positioning
A 37.1B KRW program cannot be executed by a single firm—consortium formation (lead + joint + subcontracted) is required. SME bio companies can target these roles:
SMEs can leverage strengths in niche areas (rare diseases, specific indications, Korean-population-specific data) that differentiate them from large pharma and AI firms.
Clinical Data Valuation and IP Negotiation
Key to participation is data contribution valuation and IP allocation negotiation.
Leveraging Connected R&D Programs
The K-AI program creates greater synergy when combined with other R&D initiatives:
4. KITIM Consulting Services
KITIM offers tailored consulting for bio companies considering participation:
Participation in a 37.1B KRW national R&D program can be a defining inflection point for an SME bio company's technical leap and valuation. Systematic preparation and expert advisory are critical to success. If you are evaluating participation, please contact KITIM for consultation.